- Home
- JFU vs ESLA Comparison
JFU vs ESLA Comparison
Compare JFU & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFU | ESLA |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 32.0M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JFU | ESLA |
|---|---|---|
| Price | $2.68 | $0.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 8.1K | ★ 28.3K |
| Earning Date | 12-09-2022 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $0.59 |
| 52 Week High | $9.48 | $3.15 |
Technical Indicators
Market Signals| Indicator | JFU | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 31.27 |
| Support Level | $2.06 | $0.59 |
| Resistance Level | $2.94 | $0.85 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 52.17 | 7.41 |
Price Performance
Historical ComparisonAbout JFU 9F Inc.
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.